0.175

3.74% -0.0068

After Hours: .17 -0.005 -2.86%

Lyra Therapeutics Inc (LYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Lyra Therapeutics Inc stock is traded at $0.175, with a volume of 871.37K. It is down -3.74% in the last 24 hours and down -16.67% over the past month. Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Previous Close:

$0.1818

Open:

$0.1781

24h Volume:

871.37K

Relative Volume:

0.73

Market Cap:

$11.46M

Revenue:

$1.47M

Net Income/Loss:

$-97.61M

P/E Ratio:

-0.1174

EPS:

-1.49

Net Cash Flow:

$-80.90M

1W Performance:

-7.01%

1M Performance:

-16.67%

6M Performance:

-37.50%

1Y Performance:

-97.27%

1-Day Range:

$0.175

$0.1893

1-Week Range:

$0.175

$0.2038

52-Week Range:

$0.1625

$6.79

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name

Lyra Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

617-373-4600

Address

480 ARSENAL WAY, WATERTOWN, MA

Employee

Twitter

@LyraTx

Next Earnings Date

2025-03-12

Latest SEC Filings

LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYRA Lyra Therapeutics Inc	0.175	11.46M	1.47M	-97.61M	-80.90M	-1.49
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral
May-07-24	Downgrade	Jefferies	Buy → Hold
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy
Aug-31-23	Initiated	H.C. Wainwright	Buy
May-24-22	Initiated	Cantor Fitzgerald	Overweight
May-26-20	Initiated	BTIG Research	Buy
May-26-20	Initiated	BofA/Merrill	Buy
May-26-20	Initiated	Jefferies	Buy
May-26-20	Initiated	William Blair	Outperform

View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

Mar 13, 2025

Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times

Mar 13, 2025

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 13, 2025

FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan

Mar 13, 2025

Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025

Mar 06, 2025

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital

Mar 06, 2025

Mar 05, 2025